Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

Siemens, Fast-track Diagnostics deal, 10/17

October 2017—Siemens Healthineers announced a strategic relationship with Fast-track Diagnostics that includes the addition of FTD’s broad range of CE-marked kits and multisyndromic panels to the menu of Siemens’ Versant kPCR Molecular System.

Quidel revises buy of Alere’s BNP assay business, 10/17

October 2017—Quidel announced a revised definitive agreement with Alere for its pending acquisition of Alere’s B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers under which post-acquisition, Quidel will undertake direct commercial responsibility for all BNP sales worldwide.

Women 21– 65 benefit from cervical cancer screening, 10/17

October 2017—The U.S. Preventive Services Task Force posted on Sept. 12 a draft recommendation statement and draft evidence review on screening for cervical cancer. The task force recommends that primary care clinicians screen for cervical cancer in women who are 21–29 years old every three years with cervical cytology. For women ages 30 to 65, screening is recommended with either cervical cytology alone every three years or with high-risk human papilloma virus (hrHPV) testing alone every five years.

FDA-cleared Atellica Solution, 9/17

September 2017—Siemens Healthineers showcased its Atellica Solution, flexible, scalable, automation-ready immunoassay and chemistry analyzers for laboratory diagnostics, at the 69th AACC Annual Scientific Meeting and Clinical Lab Expo. The 510(k)-cleared Atellica Solution, for mid- and high-volume labs, comprises sample management and immunoassay and chemistry analyzer components.

Ortho, Brahms agreement, 9/17

September 2017—Ortho Clinical Diagnostics announced a strategic relationship with Brahms GmbH, part of Thermo Fisher Scientific, to develop the Brahms PCT assay for use on Ortho’s Vitros Systems. The Brahms PCT assay is used in conjunction with other laboratory findings and clinical assessment to aid in sepsis management, including early identification of patients at higher risk of progressing to septic shock, identifying when it is safe to discontinue antibiotics, and establishing mortality risk in septic patients.

Streck distribution agreements, 9/17

September 2017—Streck and Inter Medico, a privately owned Canadian distributor of medical diagnostic and research-related products, have signed a distribution agreement for Streck’s cell stabilization and molecular products. Inter Medico will have exclusive distribution rights in Canada to those Streck products.

FDA-approved tests for Roche instruments, 9/17

September 2017—Roche received FDA approval for the Cobas CMV test for use on its Cobas 6800 and Cobas 8800 Systems. The test is standardized to the 1st WHO International Standard for improving harmonization in cytomegalovirus testing results across hospital institutions.

Bio-Rad quality controls, 9/17

September 2017—Bio-Rad Laboratories has added four analytes to the company’s Liquichek Tumor Marker Control. The updated control received FDA 510(k) clearance and the CE mark and is available for the immunoassay-based tumor marker testing market.

Hematology analyzer, 9/17

September 2017—Diatron displayed its Aquila three-part differential hematology analyzer at the 69th AACC annual meeting in San Diego. Specifically designed for the decentralized laboratory, this small analyzer has low reagent consumption of less than 12 mL, requires less than 20 µL of whole blood, and has a throughput of up to 60 samples per hour.